

=> d his

(FILE 'HOME' ENTERED AT 15:32:40 ON 23 FEB 2005)

FILE 'HCAPLUS' ENTERED AT 15:32:46 ON 23 FEB 2005

E W01999-US17974/AP,PRN
L1 1 W01999-US17974/AP,PRN
E US1998-95778/AP,PRN
L2 1 US1998-95778/AP,PRN
E US1998-98500/AP,PRN
L3 1 US1998-98500P/AP,PRN
E US1998-108366/AP,PRN
L4 1 US1998-108366P/AP,PRN
E US1999-119207/AP,PRN
L5 2 US1999-119207P/AP,PRN
L6 3 L1-5

FILE 'REGISTRY' ENTERED AT 15:34:48 ON 23 FEB 2005

FILE 'HCAPLUS' ENTERED AT 15:34:49 ON 23 FEB 2005

L7 TRA L6 1- RN : 219 TERMS

FILE 'REGISTRY' ENTERED AT 15:34:49 ON 23 FEB 2005

L8 219 SEA L7

FILE 'WPIX' ENTERED AT 15:34:52 ON 23 FEB 2005

E W01999-US17974/AP,PRN
L9 1 W01999-US17974/AP,PRN
E US1998-95778/AP,PRN
L10 1 US1998-95778/AP,PRN
E US1998-98500/AP,PRN
L11 1 US1998-98500/AP,PRN
E US1998-108366/AP,PRN
L12 1 US1998-108366P/AP,PRN
E US1999-119207/AP,PRN
L13 2 US1999-119207P/AP,PRN
L14 4 L9-13

FILE 'REGISTRY' ENTERED AT 15:41:19 ON 23 FEB 2005

L15 83 C15H20FNO4
L16 80 L15 AND 46.150.18/RID
L17 QUE (PMS OR MAN OR IDS)/CI OR UNSPECIFIED OR COMPD OR COMPOUND
L18 78 L16 NOT L17
L19 4 L8 AND L18
L20 3 L18 AND OCTANOIC (W) ACID
L21 75 L18 NOT L20

FILE 'HCAPLUS' ENTERED AT 15:48:01 ON 23 FEB 2005

L22 3 L20

FILE 'HCAOLD' ENTERED AT 15:48:36 ON 23 FEB 2005

L23 0 L20

FILE 'HCAPLUS' ENTERED AT 15:48:40 ON 23 FEB 2005

L24 0 OCTANOIC (1A) ACID (2A) FLUORO (1A) HYDROXYBENZOYL (1A) AMINO

=> b reg

FILE 'REGISTRY' ENTERED AT 15:50:48 ON 23 FEB 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

Search done by Noble Jarrell

STRUCTURE FILE UPDATES: 22 FEB 2005 HIGHEST RN 835870-69-4
 DICTIONARY FILE UPDATES: 22 FEB 2005 HIGHEST RN 835870-69-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide 120 tot


L20 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 800395-07-7 REGISTRY
 CN Octanoic acid, 8-[(5-fluoro-2-hydroxybenzoyl)amino]-, monosodium salt
 (9CI) (CA INDEX NAME)
 MF C15 H20 F N O4 . Na
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); USES (Uses)
 CRN (257951-76-1)



● Na

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L20 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 257951-76-1 REGISTRY
 CN Octanoic acid, 8-[(5-fluoro-2-hydroxybenzoyl)amino]- (9CI) (CA
 INDEX NAME)
 FS 3D CONCORD
 MF C15 H20 F N O4
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L20 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN
RN 257951-66-9 REGISTRY
CN Octanoic acid, 8-[(4-fluoro-2-hydroxybenzoyl)amino]- (9CI) (CA
INDEX NAME)
FS 3D CONCORD
MF C15 H20 F N O4
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b hcap
FILE 'HCAPLUS' ENTERED AT 15:50:55 ON 23 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Feb 2005 VOL 142 ISS 9
FILE LAST UPDATED: 22 Feb 2005 (20050222/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.



8-(5-Fluoro-2-hydroxy-benzoylamino)-octanoic acid



=> d his

(FILE 'HOME' ENTERED AT 15:32:40 ON 23 FEB 2005)

FILE 'HCAPLUS' ENTERED AT 15:32:46 ON 23 FEB 2005

E W01999-US17974/AP,PRN
L1 1 W01999-US17974/AP,PRN
E US1998-95778/AP,PRN
L2 1 US1998-95778/AP,PRN
E US1998-98500/AP,PRN
L3 1 US1998-98500P/AP,PRN
E US1998-108366/AP,PRN
L4 1 US1998-108366P/AP,PRN
E US1999-119207/AP,PRN
L5 2 US1999-119207P/AP,PRN
L6 3 L1-5

FILE 'REGISTRY' ENTERED AT 15:34:48 ON 23 FEB 2005

FILE 'HCAPLUS' ENTERED AT 15:34:49 ON 23 FEB 2005

L7 TRA L6 1- RN : 219 TERMS

FILE 'REGISTRY' ENTERED AT 15:34:49 ON 23 FEB 2005

L8 219 SEA L7

FILE 'WPIX' ENTERED AT 15:34:52 ON 23 FEB 2005

E W01999-US17974/AP,PRN
L9 1 W01999-US17974/AP,PRN
E US1998-95778/AP,PRN
L10 1 US1998-95778/AP,PRN
E US1998-98500/AP,PRN
L11 1 US1998-98500/AP,PRN
E US1998-108366/AP,PRN
L12 1 US1998-108366P/AP,PRN
E US1999-119207/AP,PRN
L13 2 US1999-119207P/AP,PRN
L14 4 L9-13

=> b hcap

FILE 'HCAPLUS' ENTERED AT 15:36:30 ON 23 FEB 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Feb 2005 VOL 142 ISS 9

FILE LAST UPDATED: 22 Feb 2005 (20050222/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 16 tot

L6 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:190252 HCAPLUS
 ED Entered STN: 21 Mar 2001
 TI Master automotive sensor tester
 IN Johnson, Arthur D.
 PA Echlin, Inc., USA
 SO U.S., 11 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM G08B021-00
 NCL 340660000; 073035030; 123406160; 324537000; 324384000
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6204770	B1	20010320	US 1998-95778	19980611 <--
PRAI US 1998-95778		19980611 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6204770	ICM	G08B021-00
	NCL	340660000; 073035030; 123406160; 324537000; 324384000
US 6204770	ECLA	F02D041/22D; F02P017/02 <--

AB A sensor tester for testing multiple vehicle sensors is provided comprising a circuit for testing a vehicle piezoelectric knock sensor; a circuit for testing a vehicle speed sensor; and a circuit for testing ignition coils. The circuit for testing piezoelectric knock sensors comprises an integrated circuit electrically connectable to a power source, the integrated circuit having a multiple step voltage divider, a connector for connecting the integrated circuit to the knock sensor; and a plurality of light emitting diodes electrically connected to the voltage divider of the integrated circuit. The circuit for testing vehicle speed sensors comprises a voltage divider for limiting the voltage of a power source to a reference voltage; a voltage comparator having a first input, a second input and an output, the first input electrically connected to the voltage divider, the second input electrically connected to the speed sensor; and a voltage transition detector for detecting a voltage transition from the output of the voltage comparator. The circuit for testing ignition coils that have a primary coil and a secondary coil comprises capacitance means electrically connectable in a loop with a power source and the primary coil; a first voltage indicator electrically connected in series with a side of the secondary winding and electrically connectable to the power source; a second voltage indicator for detecting a voltage across the capacitance means; a current interrupter electrically connected in parallel with the capacitance means; a first connector for connecting the power source in series with the primary coil; and a second connector for connecting the power source in series with the secondary coil.

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Abe; US 4962456 1990
- (2) Cervas; US 5359290 1994
- (3) Furuyama; US 4621602 1986
- (4) Gold; US 4401949 1983
- (5) Hirano; US Re33692 1991
- (6) Jones; US 4673868 1987
- (7) Kashiwabara; US 5119782 1992
- (8) Liu; US 5250908 1993
- (9) Masuda; US 4447801 1984
- (10) McDermott; US 4651698 1987
- (11) Ogawa; US 5235527 1993
- (12) Rizzoni; US 5687082 1997
- (13) Rohde; US 4467634 1984
- (14) Staff; US 3646438 1972

(15) Tansuwan; US 4300205 1981

(16) Walley; US 4112748 1978

L6 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:553539 HCAPLUS

DN 133:163951

ED Entered STN: 11 Aug 2000

TI Preparation of N-(.omega.-carboxyalkyl)salicylamides

IN Gschneidner, David; Bernadino, Joseph N.; Bay, William E.

PA Emisphere Technologies, Inc., USA

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07C229-14

ICS C07D265-26

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

FAN.CNT 4


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046182	A1	20000810	WO 2000-US3189	20000204 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2361716	AA	20000810	CA 2000-2361716	20000204 <--
EP 1149066	A1	20011031	EP 2000-911725	20000204 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002013497	A1	20020131	US 2001-922961	20010803 <--
US 6399798	B2	20020604		
PRAI US 1999-119207P	P	19990205 <--		
US 1999-127754P	P	19990405		
US 1999-173989P	P	19991230		
WO 2000-US3189	W	20000204		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000046182	ICM	C07C229-14
	ICS	C07D265-26
US 2002013497	ECLA	A61K009/00M6; A61K047/18; C07C231/00; C07C233/51; C07C235/24; C07C235/34; C07C235/64; C07C235/7; C07C271/28; C07C271/54; C07C271/58; C07C275/42; C07C309/59; C07C317/44; C07D239/91; C07D029/94; C07D239/96; C07D265/26; C07D311/18; C07D317/68 <--

OS CASREACT 133:163951; MARPAT 133:163951

GI



I

AB The title process utilizes protected/activated (sic) salicylamides I [R =

H; R1-R4 = H, halo, alkyl, alkoxy, etc.; R5 = protecting group; R6 = activating group (sic); R5R6 = atoms to complete a ring]. Thus, salicylamide was converted to I (R1-R4 = H, R5R6 = CO)(II; R = H) which was N-alkylated by Br(CH₂)₆CN to give II [R = (CH₂)₆CN]. The latter was hydrolyzed in 2 steps to I [R = (CH₂)₆CO₂H, R1-R6 = H].

ST carboxyalkylsalicylamide prepn; salicylamide carboxyalkyl prepn;
benzoxazinedione N alkylation

IT Alkylation

(preparation of N-(.omega.-carboxyalkyl)salicylamides)

IT 2037-95-8P, 2H-1,3-Benzoxazine-2,4(3H)-dione 4897-84-1P 24088-81-1P,
6-Chloro-2H-1,3-Benzoxazine-2,4(3H)-dione 287935-35-7P 287935-36-8P
287935-37-9P 287935-38-0P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-(.omega.-carboxyalkyl)salicylamides)

IT 183990-46-7P 183990-61-6P 183990-65-0P 204852-67-5P 257952-20-8P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of N-(.omega.-carboxyalkyl)salicylamides)

IT 65-45-2 2623-87-2, 4-Bromobutyric acid 7120-43-6, 5-Chlorosalicylamide
20965-27-9, 7-Bromoheptanenitrile 29823-21-0, Ethyl 8-bromooctanoate
55099-31-5, Ethyl 10-bromodecanoate

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of N-(.omega.-carboxyalkyl)salicylamides)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Ho; WO 9710197 A1 1997 HCAPLUS

(2) Leone-Bay; US 5773647 A 1998 HCAPLUS

L6 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:117018 HCAPLUS

DN 132:151567

ED Entered STN: 18 Feb 2000

TI Preparation of arylamidoalkylcarboxylic acids and compositions for
delivering active agents.

IN Gschneidner, David; Leone-Bay, Andrea; Wang, Eric; Errigo, Lynn; Kraft,
Kelly; Moye-Sherman, Destardi; Ho, Koc-Kan; Press, Jeffrey Bruce; Wang,
Nai Fang

PA Emisphere Technologies, Inc., USA

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07C233-25

ICS C07C237-36; C07C237-40; A61K047-18

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 27, 63

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007979	A2	20000217	WO 1999-US17974	19990806 <--
WO 2000007979	A3	20000518		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2339765	AA	20000217	CA 1999-2339765	19990806 <--
AU 9954711	A1	20000228	AU 1999-54711	19990806 <--
EP 1102742	A2	20010530	EP 1999-940967	19990806 <--

APP.

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

BR 9912975	A	20010925	BR 1999-12975	19990806 <--
TR 200100366	T2	20011121	TR 2001-200100366	19990806 <--
JP 2002522413	T2	20020723	JP 2000-563614	19990806 <--
NZ 509410	A	20030829	NZ 1999-509410	19990806 <--
RU 2233835	C2	20040810	RU 2001-106603	19990806 <--
ZA 2001000470	A	20010820	ZA 2001-470	20010117
PRAI US 1998-95778P	P	<u>19980807</u>		
US 1998-98500P	P	19980831	<--	
US 1998-108366P	P	19981113	<--	
US 1999-119207P	P	19990205	<--	
WO 1999-US17974	W	19990806	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000007979	ICM	C07C233-25
	ICS	C07C237-36; C07C237-40; A61K047-18
WO 2000007979	ECLA	A61K009/00M6; A61K047/18; C07C233/51; C07C235/24; C07C235/34; C07C235/64; C07C235/74; C07C271/2; C07C271/54; C07C271/58; C07C275/42; C07C309/59; C07C317/44; C07D239/91; C07D239/94; C07D029/96; C07D265/26; C07D311/18; C07D317/68
AB		135 Title compds. are claimed. Thus, Me azeloyl chloride was added dropwise to 2-amino-p-cresol in aqueous NaOH at 0.degree. to give a residue which was stirred with aqueous NaOH in THF to give 4-HO-5-MeC6H3NHCO(CH2)7CO2H. Title compds. at 100-300 mg/kg with parathyroid hormone at 25-200 .mu.g orally or intracolonicly in rats gave peak serum parathyroid hormone levels of 5-1459.71 pg/mL.
ST		arylamidoalkylcarboxylate prepn active agent delivery; drug delivery carrier arylamidoalkylcarboxylate prepn
IT		Drug delivery systems (carriers; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
IT		Fungicides (delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
IT		Antigens Carbohydrates, biological studies Hormones, animal, biological studies Interleukin 1 Interleukin 2 Lipids, biological studies Mucopolysaccharides, biological studies Peptides, biological studies Polysaccharides, biological studies Proteins, general, biological studies RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
IT		Mucopolysaccharides, biological studies RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (heparinoids, delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
IT		Antibodies RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (monoclonal, delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)

- IT Amides, preparation
Carboxylic acids, preparation
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT Interferons
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha., delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT Interferons
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta., delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT Interferons
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.gamma., delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT 50-56-6, Oxytocin, biological studies 70-51-9, Desferrioxamine 1404-90-6, Vancomycin 9002-60-2, Adrenocorticotropin, biological studies 9002-64-6, Parathyroid hormone 9002-68-0, Follicle stimulating hormone 9002-72-6, Growth hormone 9004-10-8, Insulin, biological studies 9005-49-6, Heparin, biological studies 9007-12-9, Calcitonin 9007-27-6, Chondroitin 9014-42-0, Thrombopoietin 9034-40-6, Gonadotropin releasing hormone 11000-17-2, Vasopressin 11096-26-7, Erythropoietin 12629-01-5, Human Growth hormone 15826-37-6, Cromolyn sodium 21215-62-3, Human calcitonin 37228-64-1, Glucocerebrosidase 38916-34-6, Somatostatin 47931-85-1, Salmon calcitonin 52232-67-4 57014-02-5, Eel calcitonin 59865-13-3, Cyclosporin 61912-98-9, Insulin-like growth factor 66419-50-9, Bovine growth hormone 67763-96-6, IGF-1 75634-40-1, Dermatan 78232-94-7 85637-73-6, Atrial natriuretic factor 121181-53-1, Filgrastim 126467-48-9, Porcine growth hormone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT 9001-92-7, Protease
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors, delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT 56-40-6, Glycine, reactions 95-84-1, 2-Amino-p-cresol 95-85-2, 2-Amino-4-chlorophenol 107-95-9, .beta.-Alanine 119-84-6 156-38-7, 4-Hydroxyphenylacetic acid 321-69-7 393-52-2, o-Fluorobenzoyl chloride 541-41-3, Ethyl chloroformate 1002-57-9, 8-Aminocaprylic acid 1076-38-6, 4-Hydroxycoumarin 2237-36-7, 4-Methoxysalicylic acid 2393-17-1, 3-(4-Aminophenyl)propionic acid 2623-87-2, 4-Bromobutyric acid 3320-86-3 3788-56-5 4101-68-2, 1,10-Dibromodecane 4376-18-5, Monomethyl phthalate 4385-48-2, 1,4-Benzodioxan-2-one 5538-51-2, O-Acetylsalicyloyl chloride 7120-43-6, 5-Chloro-2-hydroxybenzamide 13108-19-5, 10-Aminodecanoic acid 14113-01-0 15118-60-2, 4-(4-Aminophenyl)butyric acid 56555-02-3 183991-08-4 204852-59-5 257952-43-5 257952-44-6 257952-45-7 257952-46-8 257952-48-0 257952-51-5
RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)

IT 4897-84-1P. Methyl 4-bromobutanoate 24088-81-1P 164021-04-9P
257952-47-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)

IT 257951-72-7P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)

IT 363-34-8P 495-69-2P 956-09-2P 6292-94-0P 13443-58-8P 35340-63-7P
42013-20-7P 43169-73-9P 58278-22-1P 58278-23-2P 70467-21-9P
174842-78-5P 204852-65-3P 209961-41-1P 215653-68-2P 215653-69-3P
215653-70-6P 249277-59-6P 257951-23-8P 257951-24-9P 257951-25-0P
257951-26-1P 257951-27-2P 257951-28-3P 257951-29-4P 257951-30-7P
257951-31-8P 257951-32-9P 257951-33-0P 257951-34-1P 257951-35-2P
257951-36-3P 257951-37-4P 257951-38-5P 257951-39-6P 257951-40-9P
257951-41-0P 257951-42-1P 257951-43-2P 257951-44-3P 257951-45-4P
257951-46-5P 257951-47-6P 257951-48-7P 257951-49-8P 257951-50-1P
257951-51-2P 257951-52-3P 257951-53-4P 257951-54-5P 257951-55-6P
257951-56-7P 257951-57-8P 257951-59-0P 257951-61-4P 257951-63-6P
257951-65-8P 257951-66-9P 257951-67-0P 257951-68-1P 257951-69-2P
257951-70-5P 257951-71-6P 257951-73-8P 257951-74-9P 257951-75-0P
257951-76-1P 257951-77-2P 257951-78-3P 257951-79-4P 257951-80-7P
257951-81-8P 257951-82-9P 257951-83-0P 257951-85-2P 257951-86-3P
257951-87-4P 257951-88-5P 257951-89-6P 257951-90-9P 257951-91-0P
257951-92-1P 257951-93-2P 257951-94-3P 257951-95-4P 257951-96-5P
257951-97-6P 257951-98-7P 257951-99-8P 257952-00-4P 257952-01-5P
257952-02-6P 257952-03-7P 257952-04-8P 257952-05-9P 257952-06-0P
257952-07-1P 257952-08-2P 257952-09-3P 257952-10-6P 257952-11-7P
257952-12-8P 257952-13-9P 257952-14-0P 257952-15-1P 257952-16-2P
257952-17-3P 257952-18-4P 257952-19-5P 257952-20-8P 257952-21-9P
257952-22-0P 257952-23-1P 257952-24-2P 257952-25-3P 257952-26-4P
257952-27-5P 257952-28-6P 257952-29-7P 257952-30-0P 257952-31-1P
257952-32-2P 257952-33-3P 257952-34-4P 257952-35-5P 257952-36-6P
257952-37-7P 257952-38-8P 257952-39-9P 257952-40-2P 257952-41-3P
257952-42-4P 257952-49-1P 257952-50-4P 257952-79-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)

=> b wpix

FILE 'WPIX' ENTERED AT 15:36:41 ON 23 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 18 FEB 2005 <20050218/UP>
MOST RECENT DERWENT UPDATE: 200512 <200512/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:

<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> NEW DISPLAY FORMAT HITSTR ADDED ALLOWING DISPLAY OF
HIT STRUCTURES WITHIN THE BIBLIOGRAPHIC DOCUMENT <<<

>>> SMILES and ISOSMILES strings are no longer available as
Derwent Chemistry Resource display fields <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
PLEASE CHECK:
<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-revision/>
FOR DETAILS. <<<

=> d all 114 tot

L14 ANSWER 1 OF 4 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2001-334560 [35] WPIX

DNN N2001-241404

TI Master automotive sensor tester for testing multiple vehicle sensors, has
voltage indicators electrically connected to voltage divider which in turn
is connected to knock sensor.

DC S01 S02 W05 W06 X22

IN JOHNSON, A D

PA (ECHL-N) ECHLIN INC

CYC 1

PI US 6204770 B1 20010320 (200135)* 11 G08B021-00

ADT US 6204770 B1 US 1998-95778 19980611

PRAI US 1998-95778 19980611

IC ICM G08B021-00

AB US 6204770 B UPAB: 20010625

NOVELTY - The circuit for testing a piezoelectric knock sensor, has
multiple step voltage divider electrically connectable to the knock
sensor. Voltage indicators are electrically connected to the voltage
divider by an integrated circuit. The multiple step voltage divider has a
current limiter for setting the output reference voltage and the light
emitting diode current to approximately 10 milliamps.

DETAILED DESCRIPTION - The vehicle speed sensor testing circuit has a
voltage comparator with input connected to voltage divider and speed
sensor. A voltage transition detector detects voltage transition from
output of voltage comparator. The ignition coil testing circuit has a
capacitor electrically connected with power source and primary coil and in
parallel with current interrupts. A voltage meter detects voltage across
capacitor. Connectors connect the power source in series with primary and
secondary coils. An INDEPENDENT CLAIM is also included for circuit for
testing piezoelectric knock sensor.

USE - Used for testing various electronic sensors that are used in
automotive and marine vehicles.

ADVANTAGE - Automotive sensor tester are capable of testing
individually the functioning of vehicle speed sensors or ignition coils.

DESCRIPTION OF DRAWING(S) - The figure shows the top view of the
master sensor tester.

Dwg.1a/5

FS EPI

FA AB; GI

MC EPI: S01-G12; S02-F04B2; S02-F04D3A; S02-F04F; S02-J02E; W05-B09; W06-C05;
X22-A01D; X22-A05; X22-X06

L14 ANSWER 2 OF 4 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2000-524408 [47] WPIX

CR 2000-205645 [18]; 2000-647324 [62]; 2000-656201 [63]
DNC C2000-155767
TI Preparation of alkylated salicylamide derivatives used as drug delivery agents by alkylating O-protected, N-activated salicylamide.
DC B02 B05 B07
IN BAY, W E; BERNADINO, J N; GSCHNEIDNER, D; AGARWAL, R K; CHAUDHARY, K; GOLDBERG, M M; MAJURU, S; RUSSO, J P
PA (EMIS-N) EMISPHERE TECHNOLOGIES INC
CYC 90
PI WO 2000046182 A1 20000810 (200047)* EN 31 C07C229-14
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ TZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT TZ UA UG US UZ VN YU ZA ZW
AU 2000033578 A 20000825 (200059) C07C229-14
EP 1149066 A1 20011031 (200172) EN C07C229-14
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
US 2002013497 A1 20020131 (200210) C07C237-28
US 6399798 B2 20020604 (200242) C07C233-65
ZA 2001007716 A 20031126 (200402) 60 C07C000-00
EP 1175390 B1 20050202 (200510) EN C07C229-00
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
ADT WO 2000046182 A1 WO 2000-US3189 20000204; AU 2000033578 A AU 2000-33578
20000204; EP 1149066 A1 EP 2000-911725 20000204, WO 2000-US3189 20000204;
US 2002013497 A1 Provisional US 1999-119207P 19990205,
Provisional US 1999-127754P 19990405, Provisional US 1999-173989P
19991230, Cont of WO 2000-US3189 20000204, US 2001-922961 20010803; US
6399798 B2 Provisional US 1999-119207P 19990205, Provisional US
1999-127754P 19990405, Provisional US 1999-173989P 19991230, Cont of WO
2000-US3189 20000204, US 2001-922961 20010803; ZA 2001007716 A ZA
2001-7716 20010918; EP 1175390 B1 EP 2000-921909 20000405, WO 2000-US9390
20000405
FDT AU 2000033578 A Based on WO 2000046182; EP 1149066 A1 Based on WO
2000046182; EP 1175390 B1 Based on WO 2000059863
PRAI US 1999-173989P 19991230; US 1999-119207P
19990205; US 1999-127754P 19990405; US 2001-922961
20010803; US 2000-186142P 20000301; US 2000-186143P
20000301; US 2000-191286P 20000321
IC ICM C07C000-00; C07C229-00; C07C229-14; C07C233-65; C07C237-28
ICS C07C235-58; C07D265-26
AB WO 2000046182 A UPAB: 20050211
NOVELTY - Preparation of an alkylated salicylamide derivative (I)
comprises:
(1) alkylating a protected/activated salicylamide (II) with an
alkylating agent to form a protected/activated alkylated salicylamide
(III) and
(2) deprotecting and deactivating (III).
USE - (I) are useful as drug delivery agents for oral or parenteral
routes.
ADVANTAGE - The process uses cheap and readily available starting
materials and a simple and cost effective method which is amenable to
industrial scale-up for commercial production.
Dwg.0/0
FS CPI
FA AB; GI; DCN
MC CPI: B06-E03; B10-A15; B10-C04; B10-D03; B10-G02; B11-C09
L14 ANSWER 3 OF 4 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2000-205645 [18] WPIX
CR 2000-524408 [47]; 2000-647324 [62]; 2000-656201 [63]
DNC C2000-063425

TI New alkanolic acid derivatives, useful as pharmaceutical excipients in medicinal preparations.

DC B07 D16

IN ERRIGO, L; GSCHNEIDNER, D; HO, K; LEONE-BAY, A; PRESS, J B; TANG, P; WANG, E; WANG, N F; LEON-BAY, A; KRAFT, K; MOYE-SHERMAN, D; MOYESHERMAN, D

PA (EMIS-N) EMISPHERE TECHNOLOGIES INC

CYC 88

PI WO 2000007979 A2 20000217 (200018)* EN 53 C07C233-25

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ UG ZW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI
GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
UA UG US UZ VN YU ZA ZW

AU 9954711 A 20000228 (200030) C07C233-25

EP 1102742 A2 20010530 (200131) EN C07C233-25

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI

BR 9912975 A 20010925 (200161) C07C233-25

CZ 2001000449 A3 20011017 (200172) C07C233-25

ZA 2001000470 A 20011031 (200173) 59 A61K000-00

CN 1315936 A 20011003 (200205) C07C233-25

KR 2001072308 A 20010731 (200209) C07C233-25

HU 2001003188 A2 20011228 (200216) C07C233-25

JP 2002522413 W 20020723 (200263) 59 C07C233-25

MX 2001001243 A1 20020201 (200362) A61K047-18

NZ 509410 A 20030829 (200365) C07C233-25

AU 2003261486 A1 20031204 (200436)# C07C233-25

RU 2233835 C2 20040810 (200459) C07C233-25

ADT WO 2000007979 A2 WO 1999-US17974 19990806; AU 9954711 A AU 1999-54711 19990806; EP 1102742 A2 EP 1999-940967 19990806, WO 1999-US17974 19990806; BR 9912975 A BR 1999-12975 19990806, WO 1999-US17974 19990806; CZ 2001000449 A3 WO 1999-US17974 19990806, CZ 2001-449 19990806; ZA 2001000470 A ZA 2001-470 20010117; CN 1315936 A CN 1999-809438 19990806; KR 2001072308 A KR 2001-701606 20010206; HU 2001003188 A2 WO 1999-US17974 19990806, HU 2001-3188 19990806; JP 2002522413 W WO 1999-US17974 19990806, JP 2000-563614 19990806; MX 2001001243 A1 WO 1999-US17974 19990806, MX 2001-1243 20010201; NZ 509410 A NZ 1999-509410 19990806, WO 1999-US17974 19990806; AU 2003261486 A1 Div ex AU 1999-54711 19990806, AU 2003-261486 20031106; RU 2233835 C2 WO 1999-US17974 19990806, RU 2001-106603 19990806

FDT AU 9954711 A Based on WO 2000007979; EP 1102742 A2 Based on WO 2000007979; BR 9912975 A Based on WO 2000007979; CZ 2001000449 A3 Based on WO 2000007979; HU 2001003188 A2 Based on WO 2000007979; JP 2002522413 W Based on WO 2000007979; MX 2001001243 A1 Based on WO 2000007979; NZ 509410 A Based on WO 2000007979; RU 2233835 C2 Based on WO 2000007979

PRAI US 1999-119207P 19990205; US 1998-95778P 19980807; US 1998-98500P 19980831; US 1998-108366P 19981113; AU 2003-261486 20031106

IC ICM A61K000-00; A61K047-18; C07C233-25

ICS A61K031-18; A61K031-727; A61K038-22; A61K038-27; A61K047-10; A61K047-16; A61K047-22; A61P005-00; A61P005-18; C07C233-51; C07C233-54; C07C233-81; C07C233-83; C07C237-36; C07C237-40; C07C271-28; C07C275-42; C07C309-59; C07C317-44; C07D239-91; C07D239-94; C07D239-96; C07D311-68; C07D317-68

AB WO 200007979 A UPAB: 20040915

NOVELTY - 135 Specified alkanolic acid derivatives are new.

DETAILED DESCRIPTION - 135 Specific alkanolic acid derivatives and their salts are new. They include 27 compounds of formula (I), 24 compounds of formula (II), 54 compounds formula (III).

3-(N-(4-(N-(3,5-dichloro-2-hydroxybenzoyl)amino)benzoyl)propanoic acid, 6-(N-(2-hydroxybenzoyl)amino)-quinoline-2-carboxylic acid, 3-(4-fluoro or hydroxy-3-(N-(2-hydroxy-benzoyl)amino)-phenyl)propanoic acid.

4-(4-(2-hydroxyphenyl-sulfinyl or sulfonyl)phenyl)butanoic acid.
 N-(4-chloro-3-(N-(2-methoxybenzoyl)amino)benzoyl)- beta -alanine.
 4-(4-(quinazolinylamino)phenyl)butanoic acid, 3-(2-fluoro-4-(N-(2-hydroxybenzoyl)amino)-phenyl)-propanoic acid, and 9-((2-nitrophenylamino)carbonyloxy)nonanoic acid.

The compounds (I) are (I) where:

- (a) $n = 3$;
 $m = \text{CH}_2\text{O}$; and
 $X = 2\text{-OH}$ or 4-OH ; or (b)
- $n = 2$ or 3 ;
 $m = 0$; and
 $X = 5\text{-F}$ + optional 3-F ; or (c)
- $n = 3$;
 $m = 1$; and
 $X = 3\text{-OH}$ or 4-OH ; or (d)
- $n = 2$ or 3 ;
 $m = 0$; and
 $X = 2\text{-NHCH}_3$, 2-OH 3-methyl 5-fluoro or 5-chloro ; or (e)
- $n = 2$;
 $m = 0$; and
 $X = \text{NHacetyl}$; or (f)
- $n = 3$;
 $m = 0$; and
 $X = 2\text{-SO}_3\text{Na}$; or (g)
- $n = 3$;
 $m = 0$; and
 $X = 2\text{-OH}$ 4-methoxy ; or (h)
- $n = 2$ or 3 ;
 $m = 2$; and
 $X = 2\text{-OH}$; or (i)
- $n = 2$ or 3 ;
 $m = 0$; and
 $X = 2\text{-OH}$ $3,5$ dimethyl; or (j)
- $n = 2$;
 $m = 0$; and
 $X = 2\text{-OH}$ 3-bromo or fluoro 5-chloro ; or (k)
- $n = 2$;
 $m = \text{bond}$; and
 $X = 2\text{-OH}$ 3-chloro 5-fluoro ; or (l)
- $n = 2$ or 3 ;
 $m = 0$; and
 $X = 2\text{-NH}_2$ 5-F ; or (m)
- $n = 2$ or 3 ;
 $m = 0$; and
 $X = 2\text{-NH}_2$, 5-chloro with optional 3-chloro ;

The compounds (II) are (II) where:

- (a) $n' = 1\text{-}12$; and
 $X' = 2\text{-hydroxy}$ 5-chloro- ; or (b)
- $n' = 7$ and
 $X' = 2\text{-hydroxy}$ 4-fluoro- and optionally 3 fluoro- ; or (c)
- $n' = 7\text{-}8$; and
 $X' = 2\text{-OH}$ 5-fluoro- or 2-OH $3,5$ dichloro-; or (d)
- $n' = 4$ or 7 ; and
 $X' = 2\text{-OH}$ 4-methyl- ; or (e)
- $n' = 7$; and
 $X' = 2$ OH 5 methyl- or $2\text{-CH}_2\text{OH}$; or (f)
- $n' = 6$; and
 $X' = 2$ OH- ; or (g)
- $n' = 8$; and
 $X' = 2$ OH 4 methyl

The compounds (III) are (III) where:

- (a) $n'' = 1$ or $4\text{-}6$;
- $m'' = \text{bond}$; and
 $X'' = 2\text{-OH}$ 5-chloro- ; or (b)

$n'' = 1$; $m = 0$; and
 $X'' = \text{H, 2-methyl-, 2-methoxy-, or 2-fluoro-; or (c)}$
 $n'' = 1,3,5,9$ or 11 ;
 $m'' = 0$; and
 $X'' = 2\text{-OH- 4-methyl-; or (d)}$
 $n'' = 2$;
 $m'' = 0$; and
 $X'' = 2\text{-OH-; or (e)}$
 $n'' = 5$;
 $m'' = 0$; and
 $X'' = \text{H, 2-methyl-, 2-OH 4-chloro-, or 2-fluoro-; or (f)}$
 $n'' = 3,5,9,10$ or 11 ;
 $m'' = 0$ and
 $X = \text{H; or (g)}$
 $n'' = 3,9$ or 11 ;
 $m'' = 0$; and
 $X'' = 2 \text{ fluoro-; or (h)}$
 $n'' = 7$;
 $m'' = 1$; and
 $X'' = 3\text{-OH- or 4-OH-; or (i)}$
 $n'' = 7$;
 $m'' = \text{CH}_2\text{O; and}$
 $X'' = 4\text{-OH; or (j)}$
 $n'' = 7$;
 $m'' = 2$; and
 $X'' = 2\text{-OH; or (k)}$
 $n'' = 3,9$ or 11 ;
 $m'' = 0$; and
 $X'' = 2\text{-methyl- or 2-methoxy-; or (l)}$
 $n'' = 9$;
 $m'' = 0$; and
 $X'' = 2\text{-OH 5-chloro-; or (m)}$
 $n'' = 7$;
 $m'' = 0$; and
 $X'' = 2\text{-OH 3-amino 5-nitro-, 2-amino 5-fluoro or chloro-, 2-OH 3,5 difluoro-, 2-OH 3,4 difluoro-, 2-NHCH}_3\text{, 2-OH 4-fluoro-, 2-OH 3-fluoro 5-chloro-, 2-OH 3-chloro 5-fluoro-, 2-OH 3-bromo 5-chloro-, 2-OH 3,5 dimethyl-, 2-methoxy 6-chloro-, 2-OH 6-chloro-, 2-OH 5-fluoro-, or 2-OH 3-methyl 5-fluoro or chloro.}$

INDEPENDENT CLAIMS are also included for the following:

- (1) compositions comprising active agents and (I)-(III) or their salts; and
- (2) dosage unit forms comprising the composition in (1), a diluent, a disintegrant, a lubricant, a plasticizer, a colorant, and/or a dosing vehicle.

MECHANISM OF ACTION - None given.

USE - The compounds are useful as stability and bioavailability enhancers in the manufacture of medications for animals.

The sodium salt of (IIIa) (450mg) in water (2ml) was used as a delivery vehicle for salmon calcitonin (90 mu g). Water was added to make 3ml. Fasted male Sprague-Dawley rats (200-250g) were anesthetized 15 minutes before being given the solution orally with a calcitonin dose of 25 mu g/kg. The serum level of calcitonin as determined from blood collected from the tail artery was 583 plus or minus 140 pg/ml.


ADVANTAGE - Bioavailability and stability of active drugs in medicinal preparations are improved. The compounds are easy and inexpensive to make and are well suited to large scale industrial manufacturing processes.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: B06-D02; B06-D06; B10-A09B; B10-A09C; B10-C03; B10-C04; D05-H10

AN 1996-107836 [12] WPIX
DNN N1996-090257
TI Progressive power lens having curved peripheral rim and mould for its
prodn - has progressive surface portion which varies power, and peripheral
rim surface portion which does not function as effective surface, and
which surrounds progressive surface portion. 
DC P81
IN SHIRAYANAGI, M
PA (ASAO) ASAHI KOGAKU KOGYO KK; (ASAO) ASAHI OPTICAL CO LTD
CYC 5
PI GB 2292618 A 19960228 (199612)* 42 G02C007-06
DE 19530866 A1 19960229 (199614) 22 G02C007-06
FR 2723790 A1 19960223 (199615) G02C007-02
JP 08062549 A 19960308 (199620) 11 G02C007-06
GB 2292618 B 19980218 (199810) G02C007-06
US 5844657 A 19981201 (199904) G02C007-06
US 6356373 B1 20020312 (200221) G02C007-06
JP 3619264 B2 20050209 (200511) 14 G02C007-06
ADT GB 2292618 A GB 1995-17186 19950822; DE 19530866 A1 DE 1995-1030866
19950822; FR 2723790 A1 FR 1995-9982 19950822; JP 08062549 A JP
1994-197019 19940822; GB 2292618 B GB 1995-17186 19950822; US 5844657 A US
1995-517438 19950821; US 6356373 B1 Cont of US 1995-517438 19950821,
US 1998-98500 19980617; JP 3619264 B2 JP 1994-197019 19940822
FDT US 6356373 B1 Cont of US 5844657; JP 3619264 B2 Previous Publ. JP 08062549
PRAI JP 1994-197019 19940822
IC ICM G02C007-02; G02C007-06
ICS B29C039-26; B29D011-00
AB GB 2292618 A UPAB: 19960322
A progressive power lens having an effective surface includes a
progressive surface portion which progressively varies the power, and a
peripheral rim surface which does not function as an effective surface and
which is provided to surround the effective surface. The rim surface
portion is made of a curved surface.
The lens satisfies the following relationship:
(1) Df is less than or equal to 3, (2) STD (phi)/AGV (phi) is less
than or equal to 0.15, where STD (phi) stands for the standard deviation
of phi over the entire circumferential length of the lens; AVG (phi)
stands for the mean value of phi over the entire circumferential length of
the lens; Df (diopter) stands for the average surface power at a distance
reference point of the progressive surface; and, phi (degree) stands for
the angle defined by the progressive surface portion and the peripheral
rim surface portion at a boundary between them.
USE/ADVANTAGE - As plastic lens for eyeglass. Number of lens surface
covering gasket kinds is reduced due to systemisation of toric surfaces.
Dwg.2/28
FS GMPI
FA AB; GI

=> b home
FILE 'HOME' ENTERED AT 15:36:55 ON 23 FEB 2005

=>

=> d all 122 tot

L22 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:1037115 HCAPLUS
 DN 142:28169
 ED Entered STN: 03 Dec 2004
 TI Compositions for delivering peptide YY and PYY agonists
 IN Dinh, Steve; Wang, Huaizhen; Gomez-Orellana, M. Isabel
 PA Emisphere Technologies, Inc., USA
 SO PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07K
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004104018	A2	20041202	WO 2004-US15162	20040514
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005009748	A1	20050113	US 2004-846954	20040514
PRAI US 2003-470905P	P	20030514		
US 2003-471114P	P	20030515		
US 2003-506702P	P	20030925		
US 2004-536697P	P	20040114		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2004104018	ICM	C07K
---------------	-----	------

AB The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and at least one of peptide YY (PYY) and a PYY agonist. Preferably, the composition includes a therapeutically effective amount of peptide YY or the PYY agonist and the delivery agent compound. The composition of the present invention facilitates the delivery of PYY, a PYY agonist, or a mixture thereof and increases its bioavailability compared to administration without the delivery agent compound. PYY and PYY agonists possess activity as agents to reduce nutrient availability, including reduction of food intake. An liquid oral delivery agent in rats for peptide YY residues 3-36 was monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate.

ST peptide YY delivery agent SNAC

IT Antiobesity agents

Drug bioavailability

(comps. for delivering peptide YY and PYY agonists)

IT Body weight

(loss; comps. for delivering peptide YY and PYY agonists)


IT Drug delivery systems

(oral; comps. for delivering peptide YY and PYY agonists)

IT 106388-42-5, Peptide YY 126339-09-1, Peptide YY [3-36] 203787-91-1.
 Snac 264602-55-3, Snad 300718-77-8 300718-84-7, Octanoic acid,
 8-[(2-hydroxybenzoyl)amino]-, disodium salt 800395-02-2 800395-03-3

800395-04-4 800395-05-5 800395-06-6 **800395-07-7**
 800395-08-8 800395-09-9 800395-10-2 800395-12-4 800395-13-5
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (comps. for delivering peptide YY and PYY agonists)

L22 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:549162 HCAPLUS
 DN 136:107380
 ED Entered STN: 30 Jul 2001
 TI Oral delivery of biologically active parathyroid hormone
 AU Leone-Bay, Andrea; Sato, Masahiko; Paton, Duncan; Hunt, Ann H.; Sarubbi,
 Donald; Carozza, Monica; Chou, James; McDonough, James; Baughman, Robert
 A.
 CS Emisphere Technologies, Inc., Tarrytown, NY, 10591, USA
 SO Pharmaceutical Research (2001), 18(7), 964-970
 CODEN: PHREEB; ISSN: 0724-8741
 PB Kluwer Academic/Plenum Publishers
 DT Journal
 LA English
 CC 63-5 (Pharmaceuticals)
 GI



AB Parathyroid hormone (PTH), the only drug known to stimulate bone formation, is a peptide therapeutic indicated in the treatment of osteoporosis. Unfortunately, PTH is only effective when dosed by injection because it has no oral bioavailability. Herein we report the oral absorption of PTH in rats and monkeys facilitated by the novel delivery agent, N-[8-(2-hydroxy-4-methoxy)benzoyl]aminocaproic acid (I). I was selected from a group of 100 delivery agents based on in vitro chromatog. studies and in vivo screening studies in rats. The PTH/I combination was then tested in monkeys. The interaction of I and PTH was evaluated by NMR spectroscopy. Monkeys were administered an aqueous solution containing I and PTH and mean peak serum PTH concns. of about 3000 pg/mL were obtained. The relative bioavailability of oral PTH was 2.1% relative to s.c. administration. The biol. activity of the orally-delivered PTH was further evaluated in a rat model of osteoporosis. These studies showed that the bone formed following oral PTH/I administration was comparable to that formed following PTH injections. The I mediated absorption of PTH is hypothesized to be the result of a noncovalent interaction between I and PTH. The preliminary evaluation of this interaction by NMR is described. I facilitates the absorption of PTH following oral administration to both rats and monkeys. The orally-absorbed PTH is biol. active as demonstrated in a rat model of osteoporosis.

ST parathyroid hormone delivery oral benzamide deriv

IT Drug bioavailability
 (oral delivery of biol. active parathyroid hormone)

IT Drug delivery systems
 (oral; oral delivery of biol. active parathyroid hormone)

IT 956-09-2 58278-22-1 58278-23-2 78121-44-5 183990-46-7
 204852-50-6 204852-51-7 204852-71-1 209961-41-1 209962-11-8
 209962-24-3 257951-25-0 257951-32-9 257951-67-0 **257951-76-1**
 257952-03-7 257952-09-3 257952-11-7 257952-17-3 257952-23-1
 257952-27-5 345270-24-8 345270-25-9 345270-26-0 345270-28-2
 345270-30-6 345270-31-7 345270-32-8 345270-34-0 389078-58-4

389078-59-5 389078-60-8

RL: PKT (Pharmacokinetics); BIOL (Biological study)

(oral delivery of biol. active parathyroid hormone)

IT 9002-64-6, Parathyroid hormone 204852-64-2

RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral delivery of biol. active parathyroid hormone)

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Brayden, D; Pharm Res 1997, V14, P1772 HCAPLUS
- (2) Deber, C; Nat Struc Biol 1996, V10, P815
- (3) Dobnig, H; Endocrinology 1997, V138, P4607 HCAPLUS
- (4) Frost, H; Bone Miner 1992, V15, P175
- (5) Gonella, P; Adv Drug Deliv Rev 1987, V1, P235
- (6) Guarini, S; Experientia 1985, V41, P350 HCAPLUS
- (7) Humphrey, M; Delivery Systems for Peptide Drugs 1986, P139 HCAPLUS
- (8) Kalu, D; Bone Miner 1991, V15, P175 MEDLINE
- (9) Lee, V; CRC Crit Rev Ther Drug Carrier Syst 1988, V5, P69 HCAPLUS
- (10) Leone-Bay, A; Drug News and Perspectives 1996, V9, P586 HCAPLUS
- (11) Leone-Bay, A; J Control Release 1998, V50, P41 HCAPLUS
- (12) Leone-Bay, A; J Med Chem 1996, V38, P2571
- (13) Leone-Bay, A; J Med Chem 1998, V41, P1163 HCAPLUS
- (14) Marx, U; J Biol Chem 1995, V270, P15194 HCAPLUS
- (15) Milstein, S; J Control Release 1998, V53, P259 HCAPLUS
- (16) Moore, J; Curr Opin Biotech 1999, V10, P54 HCAPLUS
- (17) Ni, F; Prog Nucl Mag Reson Spectrosc 1994, V26, P517 HCAPLUS
- (18) Pidgeon, C; J Med Chem 1995, V41, P1163
- (19) Potts, J; Endocrinology, 3rd edition 1995, V2, P920
- (20) Rivera, T; Pharm Res 1997, V14, P1830 HCAPLUS
- (21) Sato, M; Bone 1995, V17(4 Suppl), P157S MEDLINE
- (22) Sato, M; Endocrinology 1997, V10, P4330
- (23) Sato, M; J Med Chem 1999, V42, P1 HCAPLUS
- (24) Sato, M; J Pharmacol Exp Ther 1995, V272, P1252 HCAPLUS
- (25) Schatz, G; Science 1996, V271, P1519 HCAPLUS
- (26) Smith, P; Adv Drug Deliv Rev 1992, V8, P253 HCAPLUS
- (27) Wronski, T; Cell and Materials 1991, V51, P69

L22 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:117018 HCAPLUS

DN 132:151567

ED Entered STN: 18 Feb 2000

TI Preparation of arylamidoalkylcarboxylic acids and compositions for delivering active agents.

IN Gschneidner, David; Leone-Bay, Andrea; Wang, Eric; Errigo, Lynn; Kraft, Kelly; Moye-Sherman, Destardi; Ho, Koc-Kan; Press, Jeffrey Bruce; Wang, Nai Fang

PA Emisphere Technologies, Inc., USA

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07C233-25

ICS C07C237-36; C07C237-40; A61K047-18

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 27, 63

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007979	A2	20000217	WO 1999-US17974	19990806
WO 2000007979	A3	20000518		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,

APP.

TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2339765 AA 20000217 CA 1999-2339765 19990806
 AU 9954711 A1 20000228 AU 1999-54711 19990806
 EP 1102742 A2 20010530 EP 1999-940967 19990806
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
 BR 9912975 A 20010925 BR 1999-12975 19990806
 TR 200100366 T2 20011121 TR 2001-200100366 19990806
 JP 2002522413 T2 20020723 JP 2000-563614 19990806
 NZ 509410 A 20030829 NZ 1999-509410 19990806
 RU 2233835 C2 20040810 RU 2001-106603 19990806
 ZA 2001000470 A 20010820 ZA 2001-470 20010117
 PRAI US 1998-95778P P 19980807
 US 1998-98500P P 19980831
 US 1998-108366P P 19981113
 US 1999-119207P P 19990205
 WO 1999-US17974 W 19990806

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000007979	ICM	C07C233-25
	ICS	C07C237-36; C07C237-40; A61K047-18
WO 2000007979	ECLA	A61K009/00M6; A61K047/18; C07C233/51; C07C235/24; C07C235/34; C07C235/64; C07C235/74; C07C271/2; C07C271/54; C07C271/58; C07C275/42; C07C309/59; C07C317/44; C07D239/91; C07D239/94; C07D029/96; C07D265/26; C07D311/18; C07D317/68
AB		135 Title compds. are claimed. Thus, Me azeloyl chloride was added dropwise to 2-amino-p-cresol in aqueous NaOH at 0.degree. to give a residue which was stirred with aqueous NaOH in THF to give 4-HO-5-MeC6H3NHCO(CH2)7CO2H. Title compds. at 100-300 mg/kg with parathyroid hormone at 25-200 .mu.g orally or intracolonicly in rats gave peak serum parathyroid hormone levels of 5-1459.71 pg/mL.
ST		arylamidoalkylcarboxylate prepn active agent delivery; drug delivery carrier arylamidoalkylcarboxylate prepn
IT		Drug delivery systems (carriers; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
IT		Fungicides (delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
IT		Antigens Carbohydrates, biological studies Hormones, animal, biological studies Interleukin 1 Interleukin 2 Lipids, biological studies Mucopolysaccharides, biological studies Peptides, biological studies Polysaccharides, biological studies Proteins, general, biological studies RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
IT		Mucopolysaccharides, biological studies RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

- (heparinoids, delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT Antibodies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (monoclonal, delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT Amides, preparation
 Carboxylic acids, preparation
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT Interferons
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.alpha., delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT Interferons
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.beta., delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT Interferons
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.gamma., delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT 50-56-6, Oxytocin, biological studies 70-51-9, Desferrioxamine
 1404-90-6, Vancomycin 9002-60-2, Adrenocorticotropin, biological studies
 9002-64-6, Parathyroid hormone 9002-68-0, Follicle stimulating hormone
 9002-72-6, Growth hormone 9004-10-8, Insulin, biological studies
 9005-49-6, Heparin, biological studies 9007-12-9, Calcitonin
 9007-27-6, Chondroitin 9014-42-0, Thrombopoietin 9034-40-6,
 Gonadotropin releasing hormone 11000-17-2, Vasopressin 11096-26-7,
 Erythropoietin 12629-01-5, Human Growth hormone 15826-37-6, Cromolyn
 sodium 21215-62-3, Human calcitonin 37228-64-1, Glucocerebrosidase
 38916-34-6, Somatostatin 47931-85-1, Salmon calcitonin 52232-67-4
 57014-02-5, Eel calcitonin 59865-13-3, Cyclosporin 61912-98-9,
 Insulin-like growth factor 66419-50-9, Bovine growth hormone
 67763-96-6, IGF-1 75634-40-1, Dermatan 78232-94-7 85637-73-6, Atrial
 natriuretic factor 121181-53-1, Filgrastim 126467-48-9, Porcine growth
 hormone
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT 9001-92-7, Protease
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibitors, delivery agents; preparation of arylamidoalkylcarboxylic acids and compns. for delivering active agents)
- IT 56-40-6, Glycine, reactions 95-84-1, 2-Amino-p-cresol 95-85-2,
 2-Amino-4-chlorophenol 107-95-9, .beta.-Alanine 119-84-6 156-38-7,
 4-Hydroxyphenylacetic acid 321-69-7 393-52-2, o-Fluorobenzoyl chloride
 541-41-3, Ethyl chloroformate 1002-57-9, 8-Aminocaprylic acid
 1076-38-6, 4-Hydroxycoumarin 2237-36-7, 4-Methoxysalicylic acid
 2393-17-1, 3-(4-Aminophenyl)propionic acid 2623-87-2, 4-Bromobutyric

acid 3320-86-3 3788-56-5 4101-68-2, 1,10-Dibromodecane 4376-18-5.
 Monomethyl phthalate 4385-48-2, 1,4-Benzodioxan-2-one 5538-51-2.
 O-Acetylsalicyloyl chloride 7120-43-6, 5-Chloro-2-hydroxybenzamide
 13108-19-5, 10-Aminodecanoic acid 14113-01-0 15118-60-2,
 4-(4-Aminophenyl)butyric acid 56555-02-3 183991-08-4 204852-59-5
 257952-43-5 257952-44-6 257952-45-7 257952-46-8 257952-48-0
 257952-51-5

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of arylamidoalkylcarboxylic acids and compns. for delivering
 active agents)

IT 4897-84-1P, Methyl 4-bromobutanoate 24088-81-1P 164021-04-9P
 257952-47-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of arylamidoalkylcarboxylic acids and compns. for delivering
 active agents)

IT 257951-72-7P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (preparation of arylamidoalkylcarboxylic acids and compns. for delivering
 active agents)

IT 363-34-8P 495-69-2P 956-09-2P 6292-94-0P 13443-58-8P 35340-63-7P
 42013-20-7P 43169-73-9P 58278-22-1P 58278-23-2P 70467-21-9P
 174842-78-5P 204852-65-3P 209961-41-1P 215653-68-2P 215653-69-3P
 215653-70-6P 249277-59-6P 257951-23-8P 257951-24-9P 257951-25-0P
 257951-26-1P 257951-27-2P 257951-28-3P 257951-29-4P 257951-30-7P
 257951-31-8P 257951-32-9P 257951-33-0P 257951-34-1P 257951-35-2P
 257951-36-3P 257951-37-4P 257951-38-5P 257951-39-6P 257951-40-9P
 257951-41-0P 257951-42-1P 257951-43-2P 257951-44-3P 257951-45-4P
 257951-46-5P 257951-47-6P 257951-48-7P 257951-49-8P 257951-50-1P
 257951-51-2P 257951-52-3P 257951-53-4P 257951-54-5P 257951-55-6P
 257951-56-7P 257951-57-8P 257951-59-0P 257951-61-4P 257951-63-6P
 257951-65-8P **257951-66-9P** 257951-67-0P 257951-68-1P
 257951-69-2P 257951-70-5P 257951-71-6P 257951-73-8P 257951-74-9P
 257951-75-0P **257951-76-1P** 257951-77-2P 257951-78-3P
 257951-79-4P 257951-80-7P 257951-81-8P 257951-82-9P 257951-83-0P
 257951-85-2P 257951-86-3P 257951-87-4P 257951-88-5P 257951-89-6P
 257951-90-9P 257951-91-0P 257951-92-1P 257951-93-2P 257951-94-3P
 257951-95-4P 257951-96-5P 257951-97-6P 257951-98-7P 257951-99-8P
 257952-00-4P 257952-01-5P 257952-02-6P 257952-03-7P 257952-04-8P
 257952-05-9P 257952-06-0P 257952-07-1P 257952-08-2P 257952-09-3P
 257952-10-6P 257952-11-7P 257952-12-8P 257952-13-9P 257952-14-0P
 257952-15-1P 257952-16-2P 257952-17-3P 257952-18-4P 257952-19-5P
 257952-20-8P 257952-21-9P 257952-22-0P 257952-23-1P 257952-24-2P
 257952-25-3P 257952-26-4P 257952-27-5P 257952-28-6P 257952-29-7P
 257952-30-0P 257952-31-1P 257952-32-2P 257952-33-3P 257952-34-4P
 257952-35-5P 257952-36-6P 257952-37-7P 257952-38-8P 257952-39-9P
 257952-40-2P 257952-41-3P 257952-42-4P 257952-49-1P 257952-50-4P
 257952-79-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (preparation of arylamidoalkylcarboxylic acids and compns. for delivering
 active agents)

=> b home

FILE 'HOME' ENTERED AT 15:51:13 ON 23 FEB 2005

=>